---
title: "Shanghai RAAS: The net profit for the third quarter was 441 million yuan, a decrease of 26.16%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262869679.md"
description: "Shanghai RAAS announced that its revenue for the third quarter was 2.139 billion yuan, an increase of 3.72% year-on-year; net profit was 441 million yuan, a decrease of 26.16%. Revenue for the first three quarters was 6.091 billion yuan, a year-on-year decrease of 3.54%; net profit was 1.471 billion yuan, a year-on-year decrease of 19.97%"
datetime: "2025-10-27T10:28:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262869679.md)
  - [en](https://longbridge.com/en/news/262869679.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262869679.md)
generator: "portal-rs"
---

# Shanghai RAAS: The net profit for the third quarter was 441 million yuan, a decrease of 26.16%

Shanghai RAAS announced that its revenue for the third quarter was 2.139 billion yuan, an increase of 3.72% year-on-year; net profit was 441 million yuan, a decrease of 26.16%. Revenue for the first three quarters was 6.091 billion yuan, a year-on-year decrease of 3.54%; net profit was 1.471 billion yuan, a year-on-year decrease of 19.97%

### Related Stocks

- [002252.CN](https://longbridge.com/en/quote/002252.CN.md)

## Related News & Research

- [Negative Link Announces Global Expansion and Next Phase of Growth](https://longbridge.com/en/news/296644416.md)
- [14:41 ETNine Corboy & Demetrio Attorneys selected to 2027 The Best Lawyers in America®](https://longbridge.com/en/news/296644470.md)
- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)
- [Genetix kicks off sickle cell disease awareness campaign](https://longbridge.com/en/news/296468544.md)
- [IMMU: Vididencel delivers durable remissions in AML and CML, with broad late-stage clinical expansion](https://longbridge.com/en/news/296462827.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**